Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

GOG-3111 / FTH-PIK-201

Trial Overview

Official Title

A Randomized, Open-label, Multi-Center, Phase 2 Clinical Trial Evaluating Sapanisertib and Serabelisib (PIKTOR) with Paclitaxel, Serabelisib with Paclitaxel, and Paclitaxel Alone in Patients with Advanced or Recurrent Endometrial Cancer

Study Purpose

To determine whether the combination of investigational drugs called sapanisertib and serabelisib with paclitaxel, or just serabelisib with paclitaxel works better at treating endometrial cancer when compared to using paclitaxel alone.

Diagnosis

Endometrioid endometrial cancer

Eligibility

Advanced or Recurrent endometrial cancer not amenable to surgery. 1-3 prior lines including platinum and immune checkpoint inhibitor.

Intervention

Arm A: Sapanisertib + Serabelisib + Paclitaxel

 

Arm B: Serabelisib + Paclitaxel

 

Arm C: Paclitaxel

For more information, go to the link below:

https://clinicaltrials.gov/study/NCT06463028?term=GOG-3111&rank=1

 

 

Key Participation Requirements
Trial Location(s)
Methodist Estabrook Cancer Center
Gender
Female
Age
19 years and older
Enrollment Status
Pending
Phase
Phase II
Methodist Health System Trial Code
FTH-PIK-201